Samsung Biologics acquires GSK's U.S. facility for US$280 mln | Yonhap News Agency
Summary
OK SEOUL, April 1 (Yonhap) -- Samsung Biologics, the biotech arm of Samsung Group, said Wednesday it has acquired a U.S. manufacturing facility from British pharmaceutical firm GSK plc for US$280 million. The facility in Rockville, Maryland, has a production capacity of 60,000 liters of drug substance, bringing Samsung Biologics' total capacity to 845,000 liters, the company said in a press release. "The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network," said John Rim, president and chief executive officer (CEO) of Samsung Biologics. Samsung Biologics said it plans to invest further to expand the facility's capacity and upgrade technologies, reinforcing its long-term commitment to strengthening the global supply chain and improving access to critical medicines. This photo, taken March 31, 2026, and provided by Samsung Biologics Co., shows the company's first overseas manufacturing facility, acquired from GSK for $280 million. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles Samsung Biologics union votes to strike over wage dispute Samsung Biologics signs vaccine partnership with CEPI (LEAD) Samsung Biologics Q4 net jumps 74 pct on operational efficiency Keywords #Samsung Biologics-US acquisition Articles with issue keywords Most Liked (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot (News Focus) Han Kang's NBCC win again spotlights art of translation (LEAD) BTS scores 7th No. 1 album on Billboard 200 with 'Arirang' Most Saved (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma (News Focus) Han Kang's NBCC win again spotlights art of translation Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot Liberal ex-prime minister to declare mayoral bid in conservative stronghold prev Samsung Biologics acquires GSK's U.S. facility for US$280 mln Next Samsung Biologics acquires GSK's U.S. facility for US$280 mln
OK SEOUL, April 1 (Yonhap) -- Samsung Biologics, the biotech arm of Samsung Group, said Wednesday it has acquired a U.S. manufacturing facility from British pharmaceutical firm GSK plc for US$280 million. The facility in Rockville, Maryland, has a production capacity of 60,000 liters of drug substance, bringing Samsung Biologics' total capacity to 845,000 liters, the company said in a press release. "The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network," said John Rim, president and chief executive officer (CEO) of Samsung Biologics. Samsung Biologics said it plans to invest further to expand the facility's capacity and upgrade technologies, reinforcing its long-term commitment to strengthening the global supply chain and improving access to critical medicines. This photo, taken March 31, 2026, and provided by Samsung Biologics Co., shows the company's first overseas manufacturing facility, acquired from GSK for $280 million. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles Samsung Biologics union votes to strike over wage dispute Samsung Biologics signs vaccine partnership with CEPI (LEAD) Samsung Biologics Q4 net jumps 74 pct on operational efficiency Keywords #Samsung Biologics-US acquisition Articles with issue keywords Most Liked (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot (News Focus) Han Kang's NBCC win again spotlights art of translation (LEAD) BTS scores 7th No. 1 album on Billboard 200 with 'Arirang' Most Saved (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma (News Focus) Han Kang's NBCC win again spotlights art of translation Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot Liberal ex-prime minister to declare mayoral bid in conservative stronghold prev Samsung Biologics acquires GSK's U.S. facility for US$280 mln Next Samsung Biologics acquires GSK's U.S. facility for US$280 mln
## Article Content
X
More
Linked in
Tumblr
Facebook Messenger
Copy URL
URL is copied.
OK
SEOUL, April 1 (Yonhap) -- Samsung Biologics, the biotech arm of Samsung Group, said Wednesday it has acquired a U.S. manufacturing facility from British pharmaceutical firm GSK plc for US$280 million.
The acquired facility marks the South Korean company's first overseas production facility.
The facility in Rockville, Maryland, has a production capacity of 60,000 liters of drug substance, bringing Samsung Biologics' total capacity to 845,000 liters, the company said in a press release.
"The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network," said John Rim, president and chief executive officer (CEO) of Samsung Biologics.
The company, as a contract development and manufacturing organization (CDMO), aims to support partners in delivering therapies to patients worldwide, with the new site expected to play a key role in that effort, he added.
Samsung Biologics said it plans to invest further to expand the facility's capacity and upgrade technologies, reinforcing its long-term commitment to strengthening the global supply chain and improving access to critical medicines.
This photo, taken March 31, 2026, and provided by Samsung Biologics Co., shows the company's first overseas manufacturing facility, acquired from GSK for $280 million. (PHOTO NOT FOR SALE) (Yonhap)
kyongae.choi@yna.co.kr
(END)
Related Articles
Samsung Biologics union votes to strike over wage dispute
Samsung Biologics signs vaccine partnership with CEPI
(LEAD) Samsung Biologics Q4 net jumps 74 pct on operational efficiency
Keywords
#Samsung Biologics-US acquisition
Articles with issue keywords
Most Liked
(2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma
Paik Kun-woo, at 80, says 'Music chose me'
(Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot
(News Focus) Han Kang's NBCC win again spotlights art of translation
(LEAD) BTS scores 7th No. 1 album on Billboard 200 with 'Arirang'
Most Saved
(2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma
(News Focus) Han Kang's NBCC win again spotlights art of translation
Paik Kun-woo, at 80, says 'Music chose me'
(Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot
Liberal ex-prime minister to declare mayoral bid in conservative stronghold
prev
Samsung Biologics acquires GSK's U.S. facility for US$280 mln
Next
Samsung Biologics acquires GSK's U.S. facility for US$280 mln
---
## Expert Analysis
### Merits
N/A
### Areas for Consideration
- This photo, taken March 31, 2026, and provided by Samsung Biologics Co., shows the company's first overseas manufacturing facility, acquired from GSK for $280 million. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles Samsung Biologics union votes to strike over wage dispute Samsung Biologics signs vaccine partnership with CEPI (LEAD) Samsung Biologics Q4 net jumps 74 pct on operational efficiency Keywords #Samsung Biologics-US acquisition Articles with issue keywords Most Liked (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot (News Focus) Han Kang's NBCC win again spotlights art of translation (LEAD) BTS scores 7th No. 1 album on Billboard 200 with 'Arirang' Most Saved (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma (News Focus) Han Kang's NBCC win again spotlights art of translation Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot Liberal ex-prime minister to declare mayoral bid in conservative stronghold prev Samsung Biologics acquires GSK's U.S. facility for US$280 mln Next Samsung Biologics acquires GSK's U.S. facility for US$280 mln
### Implications
- This photo, taken March 31, 2026, and provided by Samsung Biologics Co., shows the company's first overseas manufacturing facility, acquired from GSK for $280 million. (PHOTO NOT FOR SALE) (Yonhap) kyongae.choi@yna.co.kr (END) Related Articles Samsung Biologics union votes to strike over wage dispute Samsung Biologics signs vaccine partnership with CEPI (LEAD) Samsung Biologics Q4 net jumps 74 pct on operational efficiency Keywords #Samsung Biologics-US acquisition Articles with issue keywords Most Liked (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot (News Focus) Han Kang's NBCC win again spotlights art of translation (LEAD) BTS scores 7th No. 1 album on Billboard 200 with 'Arirang' Most Saved (2nd LD) Han Kang's 'We Do Not Part' wins NBCC Award for haunting portrayal of trauma (News Focus) Han Kang's NBCC win again spotlights art of translation Paik Kun-woo, at 80, says 'Music chose me' (Movie Review) 'Salmokji: Whispering Water': mood runs deeper than plot Liberal ex-prime minister to declare mayoral bid in conservative stronghold prev Samsung Biologics acquires GSK's U.S. facility for US$280 mln Next Samsung Biologics acquires GSK's U.S. facility for US$280 mln
### Expert Commentary
This article covers samsung, biologics, facility topics. Areas of concern are also raised. Readability: Flesch-Kincaid grade 0.0. Word count: 389.
Original Source
https://en.yna.co.kr/view/AEN20260401007000320